Pembrolizumab (Keytruda) for the treatment of previously untreated advanced melanoma without a BRAF V600 mutation
In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether pembrolizumab (trade name: Keytruda) has any advantages or disadvantages when compared with the standard treatments for people with advanced melanoma who have not had treatment before. Dacarbazine and ipilimumab are the standard treatment options.
The manufacturer provided one relevant study. One group of participants (135 people) received pembrolizumab, while another group (134 people) received ipilimumab. The results are described below.